Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variant
Anne Weiss; Franck Touret; Cecile Baronti; Magali Gilles; Bruno Hoen; Antoine Nougairede; Xavier de Lamballerie; Morten Otto Alexander Sommer.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-441457
SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide is effective against the D614G, B.1.1.7 and B.1.351 variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.
Texto completo
Documentos relacionados